Alzheimer

4

Review clinical trials related to Alzheimer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Telerehabilitation in Alzheimer's Disease

Telemedicine has developed rapidly during the COVID-19 pandemic and is now integrated into the clinical practice of many hospitals. Telemedicine offers many advantages, and even after the end of the pandemic, many patients still choose to undergo healthcare visits remotely. However, the rapid expansion of telemedicine may be associated with the risk of providing patients with unvalidated and uncontrolled telehealth solutions, potentially negatively impacting their health. In this study, the researchers aim to investigate the effectiveness of remote cognitive training in patients with mild-to-moderate Alzheimer's disease (AD) using tablets equipped with virtual reality-based cognitive exercises. The investigators also aim to evaluate the impact of online supervision of cognitive training by a neuropsychologist and to compare the costs and burden of home-based versus hospital-based cognitive training in patients with AD. This project will define the optimal modalities for cognitive telerehabilitation to ensure validated protocols for the continuity of care in AD.

Participants needed: 48
Trial details
Age: 50-90Biological sex: AllType: InterventionalSponsor: IRCCS San RaffaeleUpdated: Aug 3, 2026
Eligibility criteria

Age between 50 and 90 years. [+7]

Refusal or inability to provide written informed consent. [+14]

Status: Recruiting

Low-Dose Radiotherapy for Alzheimer's Disease

To evaluate the safety and tolerability of low-dose whole brain radiotherapy (WBRT) delivered as an induction course of 0.3 Gy × 10 fractions (3.0 Gy total) followed by 12 months of monthly maintenance LDRT (0.3 Gy × 10 fractions; 3.0 Gy total) in patients with Alzheimer's disease or dementia with inflammatory components

Participants needed: 50
Trial details
Phase: Phase 1, Phase 2Age: 50+Biological sex: AllType: InterventionalSponsor: Evan ThomasUpdated: Jul 9, 2026Locations: 1
Eligibility criteria

Age ≥50 years at time of enrollment [+8]

Prior whole brain or partial brain radiotherapy of any dose at any time [+11]

Status: Recruiting

ALZEVIT: Nationwide Digital APOE ε4 Cohort for Early Alzheimer's Disease Prevention and Trial Readiness

ALZEVIT is a nationwide, decentralized, digital-first cohort study in France designed to establish a large-scale Apolipoprotein E (APOE) genotyping registry and enable precision prevention strategies for Alzheimer's disease (AD). Sponsored by Firalis SA and conducted in collaboration with French memory centers, it addresses the need for early identification of individuals at high genetic risk, particularly APOE ε4 carriers and ε4/ε4 homozygotes, in the context of emerging disease-modifying therapies most effective in preclinical or early disease stages. Using an online recruitment platform, participants aged ≥45 years provide electronic informed consent and self-collected saliva samples via home collection kits for centralized APOE genotyping using the APO-Easy® assay, compliant with EU IVDR and US FDA requirements. Data are stored in a secure registry compliant with GDPR. Phase A (0-18 months) will enroll 50,000 participants to determine national APOE genotype distribution, identify high-risk individuals, and evaluate feasibility of large-scale digital genetic screening, with longitudinal online follow-up including cognitive and risk factor assessments. Phase B (12-24 months) includes detailed phenotyping of \~2,350 selected participants across all APOE genotypes, including \~750 ε4/ε4 homozygotes. Participants undergo clinical evaluation, MRI, cognitive testing, and multi-omics biomarker profiling (genomics, proteomics, metabolomics, environmental exposure), conducted at memory centers or via telemedicine. The study classifies participants along the cognitive continuum, including cognitively normal individuals, preclinical AD, mild cognitive impairment (MCI), and mild or moderate AD, to identify genotype-specific trajectories and modifiable risk and resilience factors. ALZEVIT aims to establish a scalable national infrastructure linking genetic stratification with longitudinal biomarker and clinical data to support prevention trials, improve understanding of APOE-related heterogeneity, and advance precision medicine for Alzheimer's disease.

Participants needed: 50,000
Trial details
Age: 45+Biological sex: AllType: ObservationalSponsor: Firalis SAUpdated: Jul 1, 2026Locations: 1
Eligibility criteria

Participants who sign the electronic Informed Consent form. [+7]

Participants who do not sign the Informed Consent form. [+12]

Status: Not yet recruiting

Assessment of Malnutrition in Hospitalized Patients: a Quasi Study

Malnutrition among hospitalized patients is a critical, yet often overlooked, public health issue associated with increased complications, longer hospital stays, higher mortality, and greater healthcare costs. In Iraq, factors such as dietary patterns, the burden of chronic diseases, and healthcare constraints may increase the risk of hospital-acquired malnutrition. Current standard care may not include systematic nutritional screening or protocol-driven support. This trial aims to test whether implementing an individualized nutritional support program can improve clinical outcomes for at-risk medical inpatients in Iraqi hospitals, building upon evidence from international studies

Participants needed: 300
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: AlFayhaa General HospitalUpdated: Mar 16, 2026Duration: 1 Month
Eligibility criteria

Age: Adult patients aged $\ge$ 18 years.Setting: Patients admitted to the Medici...

Maternity/Obstetrics: Pregnant or lactating women, as nutritional requirements a...